Tango Therapeutics Inc (TNGX) financials
Tango Therapeutics revenue and earnings by year
Tango Therapeutics's revenue was $62.4 million in the fiscal year to December 31, 2025, up 48.3% from the year before. Net income was -$102 million, -162.9% of revenue. Since the fiscal year to December 31, 2019, revenue has grown 16.7% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 62 | 42 | 37 | 25 | 37 | 8 | 25 |
| Revenue growth | 48.3% | 15.2% | 46.9% | -32.9% | 383.8% | -68.9% | — |
| Operating income | -111 | -146 | -114 | -111 | -58 | -52 | -15 |
| Operating margin | -178.4% | -346.1% | -312.6% | -446.8% | -157.1% | -681.8% | -61.5% |
| Net income | -102 | -130 | -102 | -108 | -58 | -52 | -14 |
| Net margin | -162.9% | -309.7% | -278.5% | -435.1% | -157.2% | -678.8% | -57.2% |
| Diluted EPS | -$0.87 | -$1.19 | -$1.08 | -$1.23 | -$0.92 | — | — |
| Free cash flow | -140 | -132 | -120 | -117 | -61 | 69 | -27 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open TNGX in Markets.
See also: TNGX returns
No forecast, no recommendation. This page describes Tango Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.